LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global factor VIII deficiency treatment market is projected to grow to USD 11 billion, at a CAGR of close to 6% ...
The European Medicines Agency (EMA) this week recommended granting a marketing authorization for Altuvoct (efanesoctocog alfa) for the treatment and prophylaxis of bleeding in patients with hemophilia ...
Hemophilia A is a genetic bleeding disorder caused by a deficiency in clotting factor VIII. Treatment focuses on managing bleeding episode symptoms with clotting factor replacement therapy, ...
Altuviiio temporarily replaces the missing coagulation factor VIII needed for effective hemostasis. The Food and Drug Administration (FDA) has approved Altuviiio ™ (antihemophilic factor [recombinant] ...
Hemophilia A is characterized by FVIII deficiency, leading to joint bleeds and chronic pain despite prophylactic therapy. Treatment options vary in sustaining FVIII levels, with gene therapy and ...
CAAR-T therapy may eliminate FVIII inhibitors in hemophilia A, potentially improving replacement treatment effectiveness, a study shows.
The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO®[Antihemophilic Factor (Recombinant), Fc-VWF XTEN Fusion Protein], a first-in-class, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results